| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A chilly tale of dementia
|
Morgan, Jules
|
|
|
22 |
3 |
p. 208
|
artikel
|
| 2 |
A nasal CGRP receptor antagonist for acute migraine therapy
|
Reuter, Uwe
|
|
|
22 |
3 |
p. 190-191
|
artikel
|
| 3 |
Antisense oligonucleotides in myotonic dystrophy type 1: lessons learnt
|
Sansone, Valeria A
|
|
|
22 |
3 |
p. 191-192
|
artikel
|
| 4 |
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial
|
Thornton, Charles A
|
|
|
22 |
3 |
p. 218-228
|
artikel
|
| 5 |
A spirited community that knows how to fight
|
Morgan, Jules
|
|
|
22 |
3 |
p. 204-205
|
artikel
|
| 6 |
Blue as an orange
|
Demas, Alexis
|
|
|
22 |
3 |
p. 207
|
artikel
|
| 7 |
Carpal tunnel syndrome: updated evidence and new questions
|
Padua, Luca
|
|
|
22 |
3 |
p. 255-267
|
artikel
|
| 8 |
Correction to Lancet Neurol 2022; 21: 1099–109
|
|
|
|
22 |
3 |
p. e5
|
artikel
|
| 9 |
Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria
|
Banwell, Brenda
|
|
|
22 |
3 |
p. 268-282
|
artikel
|
| 10 |
Extended-interval dosing of natalizumab in NOVA
|
Stüve, Olaf
|
|
|
22 |
3 |
p. 199-200
|
artikel
|
| 11 |
Extended-interval dosing of natalizumab in NOVA – Authors' reply
|
Foley, John F
|
|
|
22 |
3 |
p. 200-201
|
artikel
|
| 12 |
Gisele Sampaio Silva
|
|
|
|
22 |
3 |
p. 207
|
artikel
|
| 13 |
Macrophages clear the way for CNS fluid flow
|
Proulx, Steven T
|
|
|
22 |
3 |
p. 194-195
|
artikel
|
| 14 |
MOGAD comes of age with new criteria
|
Graus, Francesc
|
|
|
22 |
3 |
p. 193-194
|
artikel
|
| 15 |
Pierre Amarenco: the persistent pioneer
|
Samarasekera, Udani
|
|
|
22 |
3 |
p. 206
|
artikel
|
| 16 |
Prediction of autism in infants: progress and challenges
|
Dawson, Geraldine
|
|
|
22 |
3 |
p. 244-254
|
artikel
|
| 17 |
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial
|
Lipton, Richard B
|
|
|
22 |
3 |
p. 209-217
|
artikel
|
| 18 |
Thank you to The Lancet Neurology's peer reviewers in 2022
|
The Lancet Neurology Editors,
|
|
|
22 |
3 |
p. e1-e4
|
artikel
|
| 19 |
Towards equitable access to treatment for multiple sclerosis
|
The Lancet Neurology,
|
|
|
22 |
3 |
p. 189
|
artikel
|
| 20 |
Towards functional improvement of motor disorders associated with cerebral palsy
|
Bekteshi, Saranda
|
|
|
22 |
3 |
p. 229-243
|
artikel
|
| 21 |
Treatment-induced neuropathy of diabetes: an underdiagnosed entity
|
Quiroz-Aldave, Juan Eduardo
|
|
|
22 |
3 |
p. 201-202
|
artikel
|
| 22 |
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply
|
Elafros, Melissa A
|
|
|
22 |
3 |
p. 202
|
artikel
|
| 23 |
Treatment of asymptomatic carotid stenosis in SPACE-2
|
Goel, Akshit
|
|
|
22 |
3 |
p. 197
|
artikel
|
| 24 |
Treatment of asymptomatic carotid stenosis in SPACE-2
|
Spence, J David
|
|
|
22 |
3 |
p. 197-198
|
artikel
|
| 25 |
Treatment of asymptomatic carotid stenosis in SPACE-2 – Authors' reply
|
Reiff, Tilman
|
|
|
22 |
3 |
p. 198-199
|
artikel
|
| 26 |
Urgent need for neurological care in Ukraine
|
Tomycz, Luke D
|
|
|
22 |
3 |
p. 202-203
|
artikel
|
| 27 |
With thanks to our peer reviewers in 2022
|
Hart, Laura
|
|
|
22 |
3 |
p. 196
|
artikel
|
Tijdschrift beschrijving